MSH2 and cancer: As shown in Figure 1A and 1B, 30 patients (22.6%) were found to have germline heterozygous deleterious mutations of known cancer susceptibility genes, 9 in BRCA1, 11 in BRCA2, 2 in RAD50, 2 in TP53 and one each in ATM, BRIP1, FANCI, MSH2, MUTYH, and RAD51C. The mutation prevalence for BRCA1 and BRCA2 in this cohort was 15.0%, indicating multiple gene sequencing increasing about 7.5% of the detection rate.